Notice: This company has been marked as potentially delisted and may not be actively trading. BioTelemetry (BEAT) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrends BEAT vs. NVRO, PROF, DRTS, UTMD, ARAY, BWAY, TLSI, CATX, SKIN, and LNSRShould you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include Nevro (NVRO), Profound Medical (PROF), Alpha Tau Medical (DRTS), Utah Medical Products (UTMD), Accuray (ARAY), BrainsWay (BWAY), TriSalus Life Sciences (TLSI), Perspective Therapeutics (CATX), Beauty Health (SKIN), and LENSAR (LNSR). These companies are all part of the "surgical & medical instruments" industry. BioTelemetry vs. Nevro Profound Medical Alpha Tau Medical Utah Medical Products Accuray BrainsWay TriSalus Life Sciences Perspective Therapeutics Beauty Health LENSAR BioTelemetry (NASDAQ:BEAT) and Nevro (NYSE:NVRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations. Which has more risk and volatility, BEAT or NVRO? BioTelemetry has a beta of -0.71, meaning that its share price is 171% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Do institutionals and insiders hold more shares of BEAT or NVRO? 7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 95.5% of Nevro shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by company insiders. Comparatively, 3.2% of Nevro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, BEAT or NVRO? BioTelemetry has higher earnings, but lower revenue than Nevro. BioTelemetry is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioTelemetryN/AN/A-$14.64M-$0.68-3.00Nevro$408.52M0.54-$92.21M-$3.05-1.90 Does the media refer more to BEAT or NVRO? In the previous week, Nevro had 4 more articles in the media than BioTelemetry. MarketBeat recorded 5 mentions for Nevro and 1 mentions for BioTelemetry. Nevro's average media sentiment score of 0.02 beat BioTelemetry's score of 0.00 indicating that Nevro is being referred to more favorably in the news media. Company Overall Sentiment BioTelemetry Neutral Nevro Neutral Do analysts recommend BEAT or NVRO? BioTelemetry currently has a consensus price target of $8.00, suggesting a potential upside of 291.96%. Nevro has a consensus price target of $6.43, suggesting a potential upside of 10.87%. Given BioTelemetry's stronger consensus rating and higher possible upside, equities research analysts clearly believe BioTelemetry is more favorable than Nevro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioTelemetry 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nevro 2 Sell rating(s) 10 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.92 Is BEAT or NVRO more profitable? BioTelemetry has a net margin of 0.00% compared to Nevro's net margin of -16.54%. Nevro's return on equity of -23.52% beat BioTelemetry's return on equity.Company Net Margins Return on Equity Return on Assets BioTelemetryN/A -175.50% -154.96% Nevro -16.54%-23.52%-10.83% Does the MarketBeat Community prefer BEAT or NVRO? Nevro received 113 more outperform votes than BioTelemetry when rated by MarketBeat users. However, 63.37% of users gave BioTelemetry an outperform vote while only 62.76% of users gave Nevro an outperform vote. CompanyUnderperformOutperformBioTelemetryOutperform Votes39163.37% Underperform Votes22636.63% NevroOutperform Votes50462.76% Underperform Votes29937.24% SummaryNevro beats BioTelemetry on 9 of the 16 factors compared between the two stocks. Remove Ads Get BioTelemetry News Delivered to You Automatically Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BEAT vs. The Competition Export to ExcelMetricBioTelemetrySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.46M$4.32B$5.63B$8.09BDividend YieldN/A39.84%4.89%4.04%P/E Ratio-3.0828.1923.8318.99Price / SalesN/A50.04380.36118.67Price / CashN/A51.0838.0534.64Price / Book3.356.046.874.25Net Income-$14.64M$67.09M$3.19B$246.71M BioTelemetry Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BEATBioTelemetry1.9987 of 5 stars$2.11+1.0%$8.00+279.1%-7.6%$55.46MN/A-3.081,700Gap UpNVRONevro1.5136 of 5 stars$5.74+0.3%$6.43+12.0%-61.4%$214.90M$419.15M-3.031,215PROFProfound Medical2.2549 of 5 stars$6.99+0.9%$14.25+103.9%-14.9%$209.98M$8.98M-5.22150Earnings ReportShort Interest ↑DRTSAlpha Tau Medical2.9068 of 5 stars$2.91-3.6%$8.00+174.9%-12.8%$203.48MN/A-6.7780UTMDUtah Medical Products3.457 of 5 stars$59.23-0.6%N/A-16.7%$200.91M$40.90M14.99180ARAYAccuray2.3471 of 5 stars$1.92-4.5%N/A-34.1%$197.44M$453.14M-38.401,040BWAYBrainsWay3.5724 of 5 stars$9.34-2.2%$13.17+41.0%+53.9%$175.74M$38.63M93.41120Analyst ForecastShort Interest ↓News CoverageGap UpTLSITriSalus Life Sciences3.2442 of 5 stars$5.65-1.9%$11.56+104.6%-47.6%$172.29M$26.89M-2.27106Positive NewsCATXPerspective Therapeutics2.9085 of 5 stars$2.46-11.5%$15.14+515.6%N/A$166.27M$1.43M0.0070Analyst UpgradeAnalyst RevisionGap UpSKINBeauty Health1.5067 of 5 stars$1.28-13.3%$2.55+100.0%-62.6%$158.26M$347.62M-3.041,030LNSRLENSAR2.0434 of 5 stars$13.48+3.7%$16.00+18.7%+245.5%$156.57M$48.87M-9.23110Short Interest ↑Positive NewsGap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Nevro Alternatives Profound Medical Alternatives Alpha Tau Medical Alternatives Utah Medical Products Alternatives Accuray Alternatives BrainsWay Alternatives TriSalus Life Sciences Alternatives Perspective Therapeutics Alternatives Beauty Health Alternatives LENSAR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BEAT) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!We’re Opening the Ultimate Crypto Vault… Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioTelemetry, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioTelemetry With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BEAT Stock Alerts